Chlorotrianisene
- Generic Name
- Chlorotrianisene
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H21ClO3
- CAS Number
- 569-57-3
- Unique Ingredient Identifier
- 6V5034L121
- Background
A powerful synthetic, non-steroidal estrogen. [PubChem]
- Indication
Used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. Chlorotrianisene may also be used to prevent breast engorgement following childbirth.
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
- Conditions
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Zhongda Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06024252
A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
- Conditions
- Interventions
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 50
- Registration Number
- NCT04981665
- Locations
- 🇨🇳
the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Perioperative Therapy for Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 10
- Registration Number
- NCT04653389
- Locations
- 🇨🇳
the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
TACE(Transcatheter Arterial Chemoembolization ) Associated With Systemic Chemotherapy Versus Systemic Chemotherapy Alone in Patients With Unresectable CRLM(Colorectal Liver Metastases)
- Conditions
- Interventions
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 168
- Registration Number
- NCT03783559
- Locations
- 🇨🇳
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 49
- Registration Number
- NCT03572582
- Locations
- 🇩🇪
Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie & Endokrinologie, Hannover, Germany
Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Hunan Provincial People's Hospital
- Target Recruit Count
- 190
- Registration Number
- NCT02956772
- Locations
- 🇨🇳
The First Affiliated Hospital of University of South China, Hengyang, Hunan, China
🇨🇳Guizhou Cancer Hospital, Guiyang, Guizhou, China
🇨🇳Guizhou Province Tumor Hospital, Guiyang, Guizhou, China
Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 32
- Registration Number
- NCT02513199
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT02418988
- Locations
- 🇨🇳
Xijing Hospital of the Fourth Military Medical University, Xi An, Shanxi, China
Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma
- First Posted Date
- 2009-06-16
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT00921531
- Locations
- 🇨🇳
Liver Cancer Institute, Shanghai, Shanghai, China
Treatment of Portal Vein Tumor Thrombus After Hepatocellular Carcinoma Resection
- Conditions
- Interventions
- First Posted Date
- 2009-01-21
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT00825669
- Locations
- 🇨🇳
Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.